323 related articles for article (PubMed ID: 28527325)
1. Dyslipidemia management update.
Chang Y; Robidoux J
Curr Opin Pharmacol; 2017 Apr; 33():47-55. PubMed ID: 28527325
[TBL] [Abstract][Full Text] [Related]
2. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
3. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
5. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
6. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
Polychronopoulos G; Tziomalos K
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
[TBL] [Abstract][Full Text] [Related]
7. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia.
Cicero AFG; Bove M; Borghi C
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):9-15. PubMed ID: 29231064
[TBL] [Abstract][Full Text] [Related]
10. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?
Sahebkar A; Watts GF
Cardiovasc Drugs Ther; 2013 Dec; 27(6):559-67. PubMed ID: 23913122
[TBL] [Abstract][Full Text] [Related]
11. Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia.
Lee P; Hegele RA
Expert Opin Investig Drugs; 2013 Nov; 22(11):1411-23. PubMed ID: 23889692
[TBL] [Abstract][Full Text] [Related]
12. New therapies to reduce low-density lipoprotein cholesterol.
Wierzbicki AS; Viljoen A; Hardman TC; Mikhailidis DP
Curr Opin Cardiol; 2013 Jul; 28(4):452-7. PubMed ID: 23736819
[TBL] [Abstract][Full Text] [Related]
13. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
14. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
15. Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.
Page MM; Watts GF
Expert Opin Emerg Drugs; 2015 Jun; 20(2):299-312. PubMed ID: 25861882
[TBL] [Abstract][Full Text] [Related]
16. Emerging targets for the treatment of dyslipidemia.
Tavridou A; Ragia G; Manolopoulos VG
Curr Med Chem; 2011; 18(6):909-22. PubMed ID: 21182475
[TBL] [Abstract][Full Text] [Related]
17. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
Ito MK; Watts GF
Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a), cardiovascular disease, and contemporary management.
Jacobson TA
Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
[TBL] [Abstract][Full Text] [Related]
19. Traditional and novel non-statin lipid-lowering drugs.
Jain P
Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S38-S43. PubMed ID: 37979722
[TBL] [Abstract][Full Text] [Related]
20. [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
Thiery J; Burkhardt R
Herz; 2016 Jun; 41(4):281-9. PubMed ID: 27215417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
